TrialAnnals of the rheumatic diseases2019

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.

Sophie Glatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.